Wilson Sonsini Goodrich & Rosati represented Cleveland Diagnostics on the transaction. Cleveland Diagnostics, a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction. Iambic Therapeutics announced the closing of an oversubscribed $100 million Series B financing. The round was co-led by...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Novo Holdings A/S and Vida Ventures on the transaction. Avalyn Pharma Inc. announced the closing of an oversubscribed $175 million...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Versant Ventures and New Enterprise Associates on the deal. Nexo Therapeutics (Nexo) announced it has emerged from stealth with $60 million...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Voluware on the deal. Voluware, an award-winning provider of solutions to speed and simplify prior authorizations, announced a capital investment...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised NEA and Abingworth on the transaction. Escient Pharmaceuticals announced that it had raised $120 million through a Series C Financing...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini represented lead investors SR One and Norwest in the transaction. Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision...
You must be a Standard 1 Year member to access this content.
White & Case and Osler, Hoskin & Harcourt LLP advised Inversago Pharma Inc. on the deal, while Wilson Sonsini advised NEA. Inversago Pharma Inc., a clinical-stage...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Harmonic Discovery on the deal. Harmonic Discovery, a therapeutics company building an integrated computational and experimental platform for kinase drug...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised 1859, Inc. on the deal. 1859, Inc., a platform company combining artificial intelligence and empirical pico-scale screening data at scale...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised SR One on the deal. Simcha Therapeutics, a biotechnology company developing cytokine-based cancer immunotherapies, announced the closing of a $40...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised New Enterprise Associates (NEA) and Versant Ventures on the deal. 858 Therapeutics announced the completion of a $60 million Series...
You must be a Standard 1 Year member to access this content.
